Align Technology Financial Model
Medical Devices Company Financials Example (Free Excel Download)
Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive equity valuation and scenario planning tool for Align Technology, enabling an analyst to forecast earnings and cash flows based on clear aligner volume growth, average selling price (ASP) trends, and iTero scanner adoption.
Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software for digital orthodontics and restorative dentistry. The company operates a vertically integrated, mass-customisation business model, leveraging advanced 3D printing and digital treatment planning to deliver patient-specific orthodontic solutions.
- Business Segments: Clear Aligner (approximately 80% of revenue); Imaging Systems and CAD/CAM Services (approximately 20% of revenue).
- Key Geographies: Americas, EMEA, and APAC. International markets account for over 50% of Clear Aligner revenues and are the primary growth engine.
- Business Model Type: Asset-light manufacturing (3D printing) combined with a razor-and-blade dynamic where scanner placements drive future clear aligner utilisation.
- Competitive Position: The dominant market leader in clear aligners with over 22 million patients treated. Key competitors include Envista (Spark), Dentsply Sirona (SureSmile), and traditional wire-and-bracket orthodontic manufacturers.
- Recent Major Events: The launch of the iTero Lumina scanner in 2024/2025, significant share repurchase programmes (totalling $465.9 million in 2025), and restructuring initiatives in late 2025 to optimise manufacturing and operating costs.
The downloadable Align Technology financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsAlign Technology financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Cost of net revenues | $1.02B | $1.10B | $1.16B | $1.20B | $1.32B |
| Gross profit | $2.94B | $2.63B | $2.71B | $2.80B | $2.71B |
| Operating income | $976.4M | $642.6M | $643.3M | $607.6M | $545.8M |
| Net income | $772.0M | $362.0M | $445.0M | $421.0M | $410.0M |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Align Technology
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Clear Aligner
- Segment Name: Clear Aligner
- Revenue Driver Formula: (Comprehensive Volume x Comprehensive ASP) + (Non-Comprehensive Volume x Non-Comprehensive ASP) + Non-Case Revenues (e.g., retainers, touch-up cases).
- Historical Growth Rate: 0% to 5% CAGR over the last 3 years (2025 volume grew 4.7% YoY to 2.6 million cases, while revenue grew 0.5% YoY to $3.2 billion).
- Key Growth Levers and Headwinds: Growth is driven by teen and kid adoption (up 7.8% YoY in 2025) and international expansion. Headwinds include macroeconomic pressures on consumer discretionary spending, foreign exchange volatility, and ASP compression due to a product mix shift towards lower-priced non-comprehensive products.
- Pricing Dynamics: Contractual and volume-tiered pricing for doctors. ASPs are highly sensitive to regional mix and product mix (comprehensive vs. non-comprehensive).
- Revenue Recognition Notes: Revenue is generally recognised when the aligners are shipped, though some deferred revenue exists for mid-course corrections and retainers.
- Seasonality: Q2 and Q3 are typically stronger due to the summer teen orthodontic season, while Q1 is historically the weakest.
Imaging Systems and CAD/CAM Services (Systems and Services)
- Segment Name: Imaging Systems and CAD/CAM Services
- Revenue Driver Formula: (Scanner Units Sold x Hardware ASP) + (Active Scanners x Service/Software Subscription Fee) + exocad License Fees.
- Historical Growth Rate: 2% to 5% CAGR (2025 revenue grew 2.7% YoY to $789.6 million).
- Key Growth Levers and Headwinds: Driven by hardware upgrade cycles (e.g., iTero Lumina) and increasing penetration in general practitioner (GP) offices. Headwinds include capital equipment spending constraints in dental practices.
- Pricing Dynamics: Upfront capital purchase or lease for hardware, followed by recurring software and service subscription fees.
- Revenue Recognition Notes: Hardware revenue is recognised upon delivery or installation. Service and software revenues are deferred and recognised rateably over the contract term (typically 1 to 3 years).
- Seasonality: Q4 is often the strongest quarter for capital equipment purchases due to year-end tax incentives for dental practices.
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Direct materials (specialised polymer resins), 3D printing and manufacturing labour, scanner hardware components, freight, and overhead.
- Gross margin range: 70% to 74% on a non-GAAP basis (GAAP gross margins are typically 65% to 70% due to restructuring and accelerated depreciation).
- Key input costs and commodity exposures: Resin costs, freight rates, and manufacturing labour in Mexico and China.
- How COGS scales with revenue: High operating leverage. The marginal cost of printing an additional aligner is very low, but gross margins are negatively impacted by lower ASPs and foreign exchange headwinds.
Operating Expenses
- R&D: Typically 7% to 9% of revenue. Covers materials science, software development (ClinCheck), and scanner hardware engineering.
- SG&A: The largest expense category, typically 40% to 45% of revenue. Heavily driven by the direct sales force, doctor training, and direct-to-consumer marketing campaigns.
- Depreciation & Amortisation: Typically 4% to 6% of revenue, reflecting heavy historical investments in 3D printing capacity and software.
- Stock-Based Compensation: Significant, typically running at 4% to 6% of revenue.
- Restructuring / one-time charges: Frequent in recent years. The company incurred $67.5 million in restructuring and accelerated depreciation charges in Q4 2025 alone.
Margin Profile
- Gross margin: 70% to 72% (Non-GAAP).
- Operating margin: 20% to 23% (Non-GAAP). 2025 non-GAAP operating margin was 22.7%.
- Net margin: 18% to 20% (Non-GAAP).
- Margin trend: Stable to slightly expanding on a non-GAAP basis, though GAAP margins have been compressed by restructuring charges and FX headwinds.
Balance Sheet Structure
- Total assets: Approximately $6.0 billion to $6.5 billion.
- Key asset categories: Cash and short-term investments, accounts receivable, inventory, PP&E, and goodwill.
- Goodwill & intangibles: Approximately 15% to 20% of total assets, primarily from the acquisition of exocad.
- Working capital profile:
- Days Sales Outstanding (DSO): 60 to 70 days.
- Days Inventory Outstanding (DIO): 40 to 50 days.
- Days Payable Outstanding (DPO): 45 to 55 days.
- Net working capital as % of revenue: Typically negative or slightly positive, as deferred revenue provides a working capital benefit.
- PP&E: Consists heavily of 3D printing farms, manufacturing facilities, and computer equipment.
- Right-of-use assets / operating leases: Material, representing global office and manufacturing facility leases.
Capital Expenditure & Investment
- Capex as % of revenue: 5% to 8% historically, though normalising closer to 5% as major manufacturing build-outs in EMEA and APAC mature.
- Maintenance capex vs. growth capex: Approximately 30% maintenance, 70% growth (new 3D printers, software development, facility expansion).
- Major capex programmes: Expansion of regional manufacturing and treatment planning facilities to reduce freight costs and turnaround times.
- Capitalised software: Material, related to the continuous development of the ClinCheck software and Align Digital Platform.
- M&A pattern: Infrequent but strategic bolt-ons (e.g., exocad for CAD/CAM software integration).
Debt & Capital Structure
- Total debt: Historically zero or negligible. The company operates with a highly conservative, cash-rich balance sheet.
- Debt/EBITDA ratio: 0.0x.
- Credit rating: Unrated (no public debt).
- Key debt instruments: Unused revolving credit facility for liquidity backup.
- Share repurchase programme: Highly active. The company repurchased 2.9 million shares for $465.9 million in 2025. A new $1.0 billion programme was authorised in April 2025.
- Dividend policy: No dividend. Capital is returned exclusively through share repurchases.
Cash Flow Characteristics
- Operating cash flow conversion: Very strong, typically 1.2x to 1.5x of GAAP Net Income due to high non-cash charges (D&A, stock-based compensation) and deferred revenue growth.
- Free cash flow margin: 15% to 20% of revenue.
- Major non-cash items: Stock-based compensation, depreciation of manufacturing equipment, and restructuring asset write-downs.
- Working capital cash flow impact: Deferred revenue from scanner service contracts and comprehensive aligner treatments acts as a source of cash during growth periods.
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are generally lower than GAAP taxes due to the tax deductibility of stock-based compensation and R&D tax credits.
Sheet Structure
- Assumptions: Hardcoded drivers for volume growth, ASPs, margins, capex, and share repurchases.
- Revenue Build: Detailed build for Clear Aligner (Volume x ASP for Comprehensive and Non-Comprehensive) and Systems & Services (Hardware vs. Services).
- Income Statement: GAAP and Non-GAAP views. COGS, Gross Profit, SG&A, R&D, Restructuring, Operating Income, Tax, Net Income, and EPS.
- Balance Sheet: Assets (Cash, AR, Inventory, PP&E, Goodwill, ROU Assets) and Liabilities (AP, Accrued Liabilities, Deferred Revenue, Lease Liabilities, Equity).
- Cash Flow Statement: OCF (Net Income + D&A + SBC + WC changes), CFI (Capex), CFF (Share Repurchases), and ending cash balance.
- Debt & Equity Schedule: Tracking the $1.0 billion share repurchase authorisation, basic and diluted share count, and EPS calculations.
- Working Capital Schedule: DSO, DIO, DPO, and deferred revenue roll-forward.
- Depreciation & Capex Schedule: PP&E roll-forward, capex as a percentage of revenue, and D&A calculations.
- DCF Valuation: Unlevered free cash flow, WACC calculation, terminal value, and implied share price.
Key Financial Relationships
- Clear Aligner Revenue = (Comprehensive Volume x Comprehensive ASP) + (Non-Comprehensive Volume x Non-Comprehensive ASP) + Non-Case Revenue.
- Blended Clear Aligner ASP = Clear Aligner Revenue / Total Clear Aligner Volume.
- Systems & Services Revenue = Scanner Hardware Revenue + CAD/CAM Software & Services Revenue.
- Total Revenue = Clear Aligner Revenue + Systems & Services Revenue.
- Gross Profit = Total Revenue - Total COGS.
- Non-GAAP Operating Income = Gross Profit - SG&A - R&D (excluding stock-based compensation and restructuring charges).
- GAAP Operating Income = Non-GAAP Operating Income - Stock-Based Compensation - Restructuring Charges - Amortisation of Intangibles.
- Deferred Revenue Ending Balance = Beginning Balance + New Billings - Revenue Recognised.
- Diluted Shares Outstanding = Beginning Shares - Shares Repurchased + Shares Issued from SBC.
- Free Cash Flow = Operating Cash Flow - Capital Expenditures.
Cross-Sheet Dependencies
- The Assumptions sheet feeds the Revenue Build, Income Statement, and Working Capital Schedule.
- The Revenue Build feeds the top line of the Income Statement and drives AR and Deferred Revenue in the Working Capital Schedule.
- The Income Statement generates Net Income, which flows to the top of the Cash Flow Statement and into Retained Earnings on the Balance Sheet.
- The Working Capital Schedule calculates changes in operating assets and liabilities, which feed the Cash Flow Statement.
- The Depreciation & Capex Schedule feeds D&A into the Income Statement and Cash Flow Statement, and updates PP&E on the Balance Sheet.
- The Debt & Equity Schedule feeds share repurchases into the Cash Flow Statement and updates the share count for EPS on the Income Statement.
- The Cash Flow Statement calculates the net change in cash, which serves as the plug to balance the Balance Sheet.
Sign Convention
- Revenues, assets, and cash inflows are positive.
- Expenses, capital expenditures, share repurchases, and liabilities are positive in their respective schedules but must be subtracted in aggregation formulas (e.g., Gross Profit = Revenue - COGS).
- In the Cash Flow Statement, increases in assets are negative (use of cash), and increases in liabilities are positive (source of cash).
Things Most Likely to Go Wrong
- ASP Compression: Failing to model the decline in blended ASPs. As the company expands internationally and sells more non-comprehensive (lower-priced) products, the blended ASP naturally declines.
- FX Sensitivity: Align generates over 50% of its revenue outside the US. A strong US dollar severely depresses reported revenue and ASPs. The model must account for this headwind.
- GAAP vs. Non-GAAP Confusion: Align reports heavily on a non-GAAP basis. The builder must explicitly separate restructuring charges and stock-based compensation to bridge GAAP to non-GAAP operating margins.
- Deferred Revenue Dynamics: Systems & Services revenue includes a large deferred component. Failing to model the deferred revenue roll-forward will cause a mismatch between cash flow and reported revenue.
- Share Count Reduction: Align aggressively repurchases shares. The model must dynamically reduce the diluted share count based on the assumed repurchase dollar amount and the prevailing share price.
- Restructuring Charges: The company frequently takes restructuring charges (e.g., $67.5 million in Q4 2025). These should be modelled as non-recurring for valuation purposes but must be captured in historical GAAP reconciliations.
- Capital Expenditure Normalisation: Capex was elevated during 2021-2023 for capacity expansion. Using historical averages will overstate future capex needs; use recent lower run rates.
- Stock-Based Compensation: SBC is a massive expense for Align. Excluding it from free cash flow calculations will artificially inflate the company's valuation.
Validation Checks
- Blended Clear Aligner ASP: Must remain between $1,200 and $1,300. If it spikes above $1,300, the product mix assumption is flawed.
- Non-GAAP Gross Margin: Should remain tightly bound between 70% and 73%.
- Non-GAAP Operating Margin: Should remain between 21% and 24%.
- Capex as % of Revenue: Should normalise between 5% and 7%.
- Free Cash Flow Conversion: FCF should be roughly 80% to 100% of Non-GAAP Net Income.
- Balance Sheet Check: Total Assets must exactly equal Total Liabilities + Equity in every forecasted period.
- Debt Balance: Should remain at or near zero unless a specific M&A scenario is modelled.
- Share Count: Should decline by 1% to 3% annually based on the $1.0 billion repurchase authorisation.
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Clear Aligner Volume Growth | 4.5 | % | Based on 2025 actual volume growth of 4.7%. |
| Blended Clear Aligner ASP | 1,248 | USD | Calculated from 2025 actuals ($3.245B revenue / 2.6M cases). |
| Systems & Services Rev Growth | 3.0 | % | Based on 2025 actual growth of 2.7%. |
| Non-GAAP Gross Margin | 71.5 | % | Blended average of recent historical non-GAAP performance. |
| SG&A as % of Revenue | 42.0 | % | Historical average required to support direct sales and marketing. |
| R&D as % of Revenue | 7.5 | % | Historical average for software and materials innovation. |
| Stock-Based Comp as % of Rev | 5.0 | % | Consistent with recent historical run rates. |
| Effective Tax Rate | 20.0 | % | Estimated long-term global effective tax rate. |
| Capex as % of Revenue | 6.0 | % | Normalised rate following recent capacity expansions. |
| Annual Share Repurchases | 400 | USD Millions | Aligns with the recent $465.9M spent in 2025 and new $1B authorisation. |
| Diluted Share Count | 72.5 | Millions | Based on Q1 2025 outstanding shares and recent repurchases. |
| WACC | 9.5 | % | Standard discount rate for a high-growth, zero-debt med-tech company. |
| Terminal Growth Rate | 3.0 | % | Long-term growth assumption for the clear aligner market. |
Data Sources & Benchmarks
- SEC Filings: Align Technology Investor Relations website and SEC EDGAR (10-K, 10-Q, 8-K).
- Key Peers for Benchmarking: Envista Holdings (NVST), Dentsply Sirona (XRAY), Straumann Group (STMN.SW).
- Industry Data Sources: American Association of Orthodontists (AAO) data on case starts, dental market research reports (e.g., iData Research).
- Consensus Estimates: Bloomberg, FactSet, or Yahoo Finance for near-term revenue and EPS consensus.
Sources
- Align Technology Form 10-K for the fiscal year ended December 31, 2025 (Filed February 27, 2026).
- Align Technology Q4 2025 Financial Results Press Release (February 4, 2026).
- Align Technology Form 8-K and Earnings Presentation Slides (February 4, 2026).
- SEC EDGAR Database (https://www.sec.gov/edgar/searchedgar/companysearch.html).
- Align Technology Investor Relations (http://investor.aligntech.com).
Do more with the Align Technology model
Frequently asked
What does Align Technology do?+
Align Technology is a global medical device company that designs, manufactures, and sells the Invisalign system of clear aligners, iTero intraoral scanners, and exocad CAD/CAM software. The company operates a vertically integrated, mass-customisation business model, leveraging advanced 3D printing and digital treatment planning.
How does Align Technology generate its revenue?+
Align Technology primarily generates revenue from its Clear Aligner segment, which accounts for approximately 80% of its total revenue. The remaining 20% comes from its Imaging Systems and CAD/CAM Services segment, where iTero scanner placements drive future clear aligner utilization.
What are the key capital expenditure trends for Align Technology?+
Historically, Align Technology's capital expenditure as a percentage of revenue has been 5% to 8%, now normalizing closer to 5%. Approximately 70% of this capex is growth-related, focused on new 3D printers, software development, and facility expansion to reduce freight costs and turnaround times.
What is Align Technology's working capital profile?+
Align Technology typically exhibits a negative or slightly positive net working capital as a percentage of revenue, benefiting from deferred revenue. Its Days Sales Outstanding (DSO) ranges from 60 to 70 days, while Days Inventory Outstanding (DIO) is 40 to 50 days.
Can I download a financial model for Align Technology (ALGN)?+
Yes, a comprehensive Excel financial model for Align Technology (ALGN) is available for download. This model provides an equity valuation and scenario planning tool, enabling analysts to forecast earnings and cash flows through FY2030.
What are the main assumptions used in the Align Technology financial model?+
Key assumptions in the Align Technology financial model include a Revenue Growth rate of approximately 12.55% and COGS as a percentage of revenue around 28.27%. Other significant inputs cover R&D, SGA, and D&A as percentages of revenue, along with a 21% tax rate.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Medical Devices Company Financial Models
Browse another company in the same sector.
Abbott Laboratories
Abbott Laboratories is a diversified global healthcare company that discovers, develops, manufactures, and sells a broad line of healthcare products.
Baxter International
Baxter International Inc.
Becton Dickinson
Becton, Dickinson and Company (BD) is a leading global medical technology company that develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products.
Boston Scientific
Boston Scientific is a global developer, manufacturer, and marketer of medical devices used in a broad range of interventional medical specialties.
Cooper Companies
The Cooper Companies, Inc.
Dexcom
Dexcom is a medical device company focused on the design, development, and commercialisation of continuous glucose monitoring systems that provide real-time glucose readings for people with diabetes, replacing traditional fingerstick testing.
Edwards Lifesciences
Edwards Lifesciences is a global leader in patient-focused medical innovations for structural heart disease.
GE HealthCare
GE HealthCare is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator that provides integrated equipment, services, and data analytics to hospitals and clinicians.
Explore more Healthcare financial model templates.
